Table 3.
The impact of primary vaccination with mRNA vaccines on hospital outcomes regarding COVID-19 status and cirrhosis.
| Variable | GROUP B (n = 52) | GROUP A (n = 399) | GROUP C (n = 54) | p* | p- | p; | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer-BioNTech (n = 27) |
Moderna (n = 12) |
Pfizer-BioNTech (n = 199) |
Moderna (n = 73) |
Pfizer-BioNTech (n = 36) |
Moderna (n = 5) |
Pfizer-BioNTech | Moderna | Pfizer-BioNTech | Moderna | Pfizer-BioNTech | Moderna | |
| Encephalopathy stage | <0.001 | <0.001 | <0.001 | <0.001 | <0.05 | 0.082 | ||||||
| Stage 1-2 | 11 (21.2 | 6 (11.5) | 199 (49.9) | 72 (18) | 25 (46.3) | 1 (1.9) | ||||||
| Stage 3 | 8 (15.4) | 6 (11.5) | 0 (0) | 1 (0.3) | 7 (13) | 2 (3.7) | ||||||
| Stage 4 | 8 (15.4) | 0 (0) | 0 (0) | 0 (0) | 4 (7.4) | 2 (3.7) | ||||||
| Ascites grade | <0.001 | <0.001 | <0.001 | <0.001 | 0.094 | 0.503 | ||||||
| Mild | 0 (0) | 0 (0) | 199 (49.9) | 72 (18) | 10 (18.5) | 0 (0) | ||||||
| Moderate | 6 (11.5) | 5 (9.6) | 0 (0) | 1 (0.3) | 3 (5.6) | 3 (5.6) | ||||||
| Severe | 21 (40.4) | 7 (13.5) | 0 (0) | 0 (0) | 23 (42.6) | 2 (3.7) | ||||||
| Esophageal varices | <0.001 | <0.001 | <0.001 | <0.001 | 0.162 | 0.412 | ||||||
| Grade 1 | 3 (5.8) | 0 (0) | 1 (0.3) | 1 (0.3) | 4 (7.4) | 0 (0) | ||||||
| Grade 2 | 15 (28.8) | 8 (15.4) | 1 (0.3) | 0 (0) | 14 (25.9) | 1 (1.9) | ||||||
| Grade 3 | 6 (11.5) | 1 (1.9) | 0 (0) | 0 (0) | 7 (13) | 1 (1.9) | ||||||
| Oxygen support | 9 (17.3) | 6 (11.5) | 65 (16.3) | 29 (7.3) | 1 (1.9) | 1 (1.9) | <0.05 | 0.517 | 0.945 | 0.505 | <0.05 | 0.267 |
| Mechanical ventilation | 16 (30.8) | 4 (7.7) | 89 (22.3) | 22 (5.5) | 5 (9.3) | 1 (1.9) | <0.001 | 0.861 | 0.156 | 0.825 | <0.001 | 0.594 |
| Fatal outcome | 4 (7.7) | 0 (0) | 25 (6.3) | 6 (1.5) | 3 (5.6) | 2 (3.7) | 0.706 | <0.05 | 0.743 | 0.306 | 0.422 | <0.05 |
Categorical variables are presented as frequency (percentage). Bold text highlights the statistically significant values. GROUP A: 399 COVID-19 patients without cirrhosis. GROUP B: 52 COVID-19 patients with cirrhosis. GROUP C: 54 patients with cirrhosis without COVID-19 infection. p*: Kruskal–Wallis, chi-square and analysis of variance as appropriate among the 3 groups. p- < 0.05 statistically significant between GROUP A and GROUP B receiving different mRNA vaccines. p; < 0.05 statistically significant between GROUP B and GROUP C receiving different mRNA vaccines.